Latest News in Parkinson Disease: Treatment Progress, Cognition Improvements, and More
An overview of the latest news in Parkinson disease reported across MJH Life Sciences™.
An overview of the latest news in
FDA Approves Investigational NDA for Ketamine in Levodopa-Induced Dykinesia
As the gold standard of treatment for PD, levodopa effectively reduces parkinsonian symptoms, although long-term use has been linked with several adverse events. Chief among these, frequency of
There are
A phase 2 clinical trial evaluating the safety, efficacy, and pharmacokinetics of ketamine compared with the active control treatment of midazolam is expected to begin patient enrollment in the third quarter of this year. Pending success, the manufacturer noted that it will seek an agreement with the FDA to proceed to a phase 3 clinical study next year.
Novel Treatment Associated With Cognition Improvement in PD, Alzheimer Disease
According to recently published interim results from an ongoing phase 2a clinical trial of ANVS401, an investigational therapy intended to halt the production of
As reported by
The announcement marks ANVS401 as the first treatment examined in a double-blind, placebo-controlled study to demonstrate cognitive improvements in patients with AD using ADAS-Cog11 and functional improvements in patients with PD as measured by the
Neurological Disease Link With COVID-19 Severity, Death
In assessing risk for worse COVID-19 disease severity and death, results of a study reported by
Collecting data from COVID-19–positive (n = 1167) and COVID-19–negative (n = 11,696) individuals from UK Biobank, risk factors identified as significant after being evaluated via stepwise model regression included AD (odds ratio [OR[, 5.700; 95% CI, 3.709-8.762; P < .001), PD (OR, 2.242; 95% CI, 1.511-3.328; P <.001), and other forms of dementia (OR, 3.412; 95% CI, 2.234-5.213; P < .001).
Furthermore, univariable analysis that used death as a dependent variable showed that all-cause dementia (OR, 2.171; 95% CI, 1.231-3.900; P = .008) and AD (OR, 2.766; 95% CI, 1.123-7.420; P = .032) were associated with higher risk of COVID-19–related death independent of age. African ethnicity was also found to be associated with higher risk of death in COVID-19–positive inpatients.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Related Articles
- Promising Early Efgartigimod Response Data for Generalized Myasthenia Gravis
September 18th 2025
- Iron Dysregulation Linked to MS Progression, Review Finds
September 18th 2025
- Metabolic Issues More Common in Patients With HIV
September 18th 2025
- Barriers to Gender-Affirming Surgery Persist Despite High Satisfaction Rate
September 18th 2025